Connect with us


Kyriakides calls on Astra Zeneca to respect delivery schedules for its vaccine




In response to AstraZeneca’s announcement that they were expecting to make shortfalls in the delivery of its COVID-19 vaccine, Health Commissioner Stella Kyriakides has written to AstraZeneca stressing the importance of meeting the delivery schedules laid out in its agreement with the EU. 

Kyriakides reiterated in the letter that the scaling up of the production capacity has to happen concurrently with the conduct of clinical trials to ensure the availability of the vaccines as quickly as possible. The European Medicines Agency (EMA) has not yet given its authorization - a point that has led to criticism from EU states. Her spokesperson said that the scaling up of production was an important premise of the contract. 

The issue will be discussed in a meeting of the steering board made up of the European Commission, member states and the company today (25 January) where it will be made clear that the EU expects contractual obligations to be met. 

Chief Spokesperson for the European Commission Eric Mamer added that European Commission President had spoken with the CEO of AstraZeneca, where she reminded him that the EU has invested significant amounts in scaling up production.  However, she also recognized that production issues can appear with a complex vaccine.

Despite the publicized supply problems at vaccine manufacturer AstraZeneca, Peter Liese MEP (EPP, DE)  said: "AstraZeneca's announcement to reduce the planned supply for the EU from 80 million to 31 million doses in the first quarter must not and will not be the last word. [...] they are apparently delivering to other parts of the world, including the UK without delay. The flimsy justification that there are difficulties in the EU supply chain but not elsewhere does not hold water, as it is of course no problem to get the vaccine from the UK to the continent. 

“The company cannot be interested in permanently damaging its reputation in the world's largest single market. Many in the company seem to be embarrassed by the matter. That's why I expect a change in the delivery plans for the EU in the next few hours, and an accelerated one at that. Even the 31 million doses, however, would be a significant improvement in the situation in the EU.”


Share this article: